ALEMBIC PHARMACEUTICALS LTD. - 533573 - Statement Of Investor Complaints For The Quarter Ended March 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0660 Name of the Signatory :- Charandeep Singh SalujaDesignation :- Company Secretary and Compliance Officer
Alembic Pharma gets tentative USFDA nod for generic version of Dabigatran Etexilate capsules
The tentative approval by the US Food Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) for Dabigatran Etexilate capsules of strengths 75 mg, 110 mg, and 150 mg, Alembic said in a statement. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Tentative Approval for Dabigatran Etexilate Capsules, 75 mg, 110 mg, and 150 mg. Please find enclosed herewith our press release. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Intimation
Pursuant to Regulation 30 of the Listing Regulations, 2015, please find enclosed herewith a specimen copy of the letter (excluding the annexures) sent to the shareholders holding shares in physical form in compliance with the SEBI Circular No. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2021/655 dated 3rd November, 2021 read with SEBI Circular No. SEBl/HO/MIRSD/MIRSD_RTAMB/P/CIR/2021/687 dated 14th December, 2021 (collectively referred to as 'SEBI Circulars') requesting them to furnish their PAN, KYC details and Nomination details (including declaration to opt out) to the Registrar and Share Transfer Agent of the Company, i.e., Link Intime India Private Limited. Further, in compliance with the said SEBI Circulars, the Company has also placed the communication/intimation in this regard on its website at https://alembicpharmaceuticals.com/ We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Closure of Trading Window
With reference to the captioned matter, this is to inform the exchange that in terms of the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives framed pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in securities of the Company will remain closed from 1st April, 2022 till 48 hours after the declaration of the audited financial results for the quarter and financial year ended 31st March, 2022. The date of the Board Meeting for inter alia considering the audited financial results for the quarter and financial year ended 31st March, 2022 will be intimated in due course. We request you to kindly take the same on record.
Alembic Pharma fully acquires Aleor Dermaceuticals from JV partner
Picks up remaining 40% stake from JV partner Orbicular Pharmaceutical ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Scheme of Arrangement
The Board of Directors of the Company at its adjourned meeting held on 29th March, 2022, on recommendation of the Audit Committee has also considered and approved the Scheme of Arrangement in the nature of Amalgamation of Aleor Dermaceuticals Limited ('Transferor Company') with Alembic Pharmaceuticals Limited ('Transferee Company') and their respective shareholders under Sections 230 to 232 of the Companies Act, 2013 and rules framed thereunder ('Scheme'). ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Acquisition
This is to inform the exchange that pursuant to the approval granted by the Board of Directors at its meeting held on 28th March, 2022, the Company has entered into Share Purchase Agreement with Orbicular Pharmaceutical Technologies Private Limited (Orbicular), joint venture partner in Aleor Dermaceuticals Limited (Aleor) to acquire the 40% stake held by them in Aleor. Pursuant to said acquisition, Aleor becomes a wholly-owned subsidiary of the Company. Further, the Board of Directors of the Company at its adjourned meeting held on 29th March, 2022, on recommendation of the Audit Committee has also considered and approved the Scheme of Arrangement in the nature of Amalgamation of Aleor Dermaceuticals Limited ('Transferor Company') with Alembic Pharmaceuticals Limited ('Transferee Company') and their respective shareholders under Sections 230 to 232 of the Companies Act, 2013 and rules framed thereunder ('Scheme'). ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that the share certificate(s) of the Company has been reported as lost/misplaced and the registered shareholder(s) have requested the Company for issue of duplicate share certificate(s). We enclose herewith an e-mail intimation(s) received from Link lntime India Private Limited, Registrar and Share Transfer Agent giving the proof of the date of receipt of aforesaid information by the Company. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Lacosamide Tablets USP, 50 mg, 100 mg, 150 mg, and 200 mg. Please find enclosed herewith our press release. We request you to kindly take the same on record.